Novartis is teeing up $300 million to expand its development and manufacturing operations to bolster its push into biologic medicines. The company, which has been on a cost-cutting spree, said it will spend $110 million to increase clinical manufacturing operations at its facility in Mengeš, Slovenia, and another $60 million to expand capacity at its site in Schaftenau, Austria. Source: Fierce Pharma 13/9/2022